Modeyso's approval offers a new treatment for diffuse midline glioma with H3 K27M mutation, a previously untreatable condition beyond radiation. The drug is well-tolerated, with minimal side effects, ...
Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available. The U.S. Food and Drug Administration (FDA) ...
A human brain network associated with survival in children with diffuse midline glioma (DMG), the deadliest childhood brain cancer, has been identified by UCL clinician-scientists, raising the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results